Global Oral Solid Dosage Contract Manufacturing Market Size study, By Product Type (Tablets, Capsules, Powders, Others), By Mechanism (Immediate Release, Delayed Release, Controlled Release), and Regional Forecasts 2022-2028

Global Oral Solid Dosage Contract Manufacturing Market Size study, By Product Type (Tablets, Capsules, Powders, Others), By Mechanism (Immediate Release, Delayed Release, Controlled Release), and Regional Forecasts 2022-2028Global Oral Solid Dosage Contract Manufacturing Market is valued at approximately USDXX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2028. Oral solid dosage (OSD) products are manufactured in various shapes, and with different facility designs and production techniques. Oral solid dosage is designed in various forms such as tablets, capsules, powders, and others. The rising technological advancements in oral solid dosage forms, growing demand for novel therapies, and increasing R&D investments by CMOs & CDMOs are the primary factors stimulating the growth of the global market. For instance, in 2021, the FDA approved 50 novel drugs, 22 of which were tablets or capsules in the United States. Likewise, as per an article published in Pharma Manufacturing, tablets are highly preferred as a solid dosage form, which is estimated to have sales of above USD 500,000 by 2027. In 2018, there were around 7 capsules of solid dose and 24 solid dose tablets forms among the 59 new molecular entities approved. Accordingly, rising FDA approvals for solid dosages are fueling the demand for Oral Solid Dosage Contract Manufacturing, which, in turn, augments the market growth across the globe. However, strict approval criteria by regulatory authorities and a dearth of experienced technical staff, as well as physical capability impede the growth of the market over the forecast period of 2022-2028. Also, the growing health awareness and substantial development of the pharmaceutical industry are anticipated to act as catalyzing factors for the market demand during the forecast period.

The key regions considered for the global Oral Solid Dosage Contract Manufacturing Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. Asia Pacific is the leading region across the world in terms of market share owing to the growing production of generic drugs and rapid advancement of drug delivery technology. Whereas, North America is anticipated to exhibit a considerable growth rate over the forecast period 2022-2028. Factors such as the increasing number of drug approval by FDA, as well as growing investment in the R&D activities, would create lucrative growth prospects for the Oral Solid Dosage Contract Manufacturing Market across the North American region.

Major market players included in this report are:

Catalent, Inc.
Lonza Group
Piramal Pharma Solutions
Aenova
Jubilant
Boehringer Ingelheim
AbbVie Contract Manufacturing
Patheon
Recipharm
Next Pharma AB

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product Type:
Tablets
Capsules
Powders
Others
By Mechanism:
Immediate Release
Delayed Release
Controlled Release
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Oral Solid Dosage Contract Manufacturing Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors


Companies Mentioned

Catalent, Inc.
Lonza Group
Piramal Pharma Solutions
Aenova
Jubilant
Boehringer Ingelheim
AbbVie Contract Manufacturing
Patheon
Recipharm
Next Pharma AB

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.